U.S. health agencies, the European drug regulator and 16 top drugmakers will collaborate on vaccine and drug development efforts to fight the coronavirus pandemic, the U.S. National Institutes of Health said.
Mergers and acquisitions in the pharmaceutical industry are not only a positive for the company that has made a bid for another company, but it is also good for the industry as a whole because of increases in efficiency across the entire field, according to Atlas Venture partner Bruce Booth.
Big pharma has largely gotten out of the antibiotics business, with about 90 percent of research on new antibiotics being conducted by small biotech companies with market caps of less than $100 million, more than half pre-revenue.
Some of the industry’s largest pharmaceutical companies, including Pfizer Inc. and Eli Lilly and Co., have developed a blockchain-based system to track prescription drugs across the supply chain to better halt the flow of counterfeit medicines.
Drugmakers including Bristol-Myers Squibb Co., Gilead Sciences Inc. and Biogen Inc. hiked U.S. list prices on more than 50 drugs to begin 2020, bringing total New Year’s Day drug price increases to more than 250, according to data analyzed by 3 Axis Advisors.
A new study conducted by the Pacific Research Institute (PRI) found that wider adoption of biosimilars in the United States would create significant savings to state Medicaid programs and consumers with commercial insurance.
Consolidation in the U.S. healthcare industry, which has already witnessed a string of multi-billion dollar deals, is expected to remain a major theme for the rest of 2019.
As GlaxoSmithKline continues to evolve the company’s business structure under Chief Executive Officer Emma Walmsley, another leadership change occurred as Jack Bailey – head of the U.S. pharmaceuticals business – is stepping down at the end of 2019.
Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi, and six major health systems.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
